Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:methylphenidate
|
| gptkbp:age |
adolescents
children |
| gptkbp:approvalYear |
2006
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
N06BA04
|
| gptkbp:brand |
methylphenidate transdermal system
|
| gptkbp:controlledSubstanceSchedule |
gptkb:Schedule_II
|
| gptkbp:countryOfOperation |
gptkb:United_States
|
| gptkbp:effect |
up to 9 hours
|
| gptkbp:form |
musical composition
|
| gptkbp:genericAvailable |
no
|
| https://www.w3.org/2000/01/rdf-schema#label |
Daytrana
|
| gptkbp:indication |
ADHD
|
| gptkbp:manufacturer |
Noven Pharmaceuticals
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:removalTime |
after 9 hours
|
| gptkbp:routeOfAdministration |
transdermal
|
| gptkbp:sideEffect |
nausea
insomnia skin irritation irritability decreased appetite |
| gptkbp:usedFor |
gptkb:attention_deficit_hyperactivity_disorder
|
| gptkbp:bfsParent |
gptkb:methylphenidate
|
| gptkbp:bfsLayer |
6
|